Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of ($0.11), $0.08 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $70.9 million versus the consensus estimate of $73.6 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.